tiprankstipranks
Tonix Pharma (TNXP)
NASDAQ:TNXP

Tonix Pharma (TNXP) AI Stock Analysis

Compare
4,379 Followers

Top Page

TN

Tonix Pharma

(NASDAQ:TNXP)

52Neutral
Tonix Pharma's overall score reflects a challenging financial position alongside promising technical momentum and strategic corporate developments. Financial struggles and valuation concerns weigh down the score, but recent positive corporate events and technical indicators suggest potential future growth opportunities.

Tonix Pharma (TNXP) vs. S&P 500 (SPY)

Tonix Pharma Business Overview & Revenue Model

Company DescriptionTonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.
How the Company Makes MoneyTonix Pharmaceuticals primarily generates revenue through strategic partnerships, licensing agreements, and collaborations with other pharmaceutical and biotechnology companies. By advancing its clinical-stage candidates through various stages of research and development, Tonix aims to achieve milestones that trigger payments from partners or licensees. Additionally, upon successful commercialization of its drug candidates, the company expects to earn revenue from product sales, royalties, and milestone payments. As a company in the clinical development phase, Tonix may also rely on funding from grants or government contracts to support its research efforts.

Tonix Pharma Financial Statement Overview

Summary
Tonix Pharma faces financial challenges with persistent net losses, negative EBIT and EBITDA, and a high debt-to-equity ratio. While there is some revenue growth and equity stability, profitability and cash management remain significant concerns.
Income Statement
30
Negative
Tonix Pharma's income statement shows a challenging financial position with consistent net losses and negative EBIT and EBITDA margins, indicating operational inefficiency. The revenue growth from zero to $11.29M TTM is a positive sign, but profitability remains a significant concern.
Balance Sheet
40
Negative
The balance sheet reveals a stable equity base but with a concerning debt-to-equity ratio, given the biotech industry's typical reliance on equity funding. The company's equity ratio is healthy, reflecting a low level of liabilities relative to assets, yet the overall financial health is undermined by persistent losses.
Cash Flow
35
Negative
The cash flow statement highlights a negative free cash flow trend, though operating cash flow shows some improvement. The high negative free cash flow relative to net income suggests cash management issues, but the company has successfully raised financing, which helps ease liquidity concerns.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
11.29M7.77M0.000.000.000.00
Gross Profit
851.00K3.03M-112.09M-92.31M-50.51M-28.83M
EBIT
-82.59M-118.38M-112.09M-92.31M-50.51M-28.83M
EBITDA
-79.16M-114.09M-110.84M-92.26M-50.48M-28.80M
Net Income Common Stockholders
-135.25M-116.66M-116.88M-92.29M-52.17M-31.09M
Balance SheetCash, Cash Equivalents and Short-Term Investments
25.03M24.95M120.23M178.66M77.07M11.25M
Total Assets
26.32M154.46M225.69M240.90M98.18M14.56M
Total Debt
0.009.81M760.00K956.00K1.31M358.00K
Net Debt
-25.03M-15.13M-119.47M-177.70M-75.76M-10.89M
Total Liabilities
2.65M48.93M18.51M22.18M10.54M5.14M
Stockholders Equity
23.66M105.53M207.18M218.72M87.65M9.42M
Cash FlowFree Cash Flow
-68.46M-109.90M-146.20M-110.86M-57.13M-26.70M
Operating Cash Flow
-67.53M-102.00M-98.05M-75.56M-48.57M-26.68M
Investing Cash Flow
-215.60K-29.07M-48.15M-35.31M-8.56M-17.00K
Financing Cash Flow
90.89M36.52M87.84M212.49M123.11M12.92M

Tonix Pharma Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price13.41
Price Trends
50DMA
20.84
Negative
100DMA
21.16
Negative
200DMA
60.33
Negative
Market Momentum
MACD
-2.03
Negative
RSI
48.04
Neutral
STOCH
56.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNXP, the sentiment is Neutral. The current price of 13.41 is above the 20-day moving average (MA) of 10.51, below the 50-day MA of 20.84, and below the 200-day MA of 60.33, indicating a neutral trend. The MACD of -2.03 indicates Negative momentum. The RSI at 48.04 is Neutral, neither overbought nor oversold. The STOCH value of 56.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TNXP.

Tonix Pharma Risk Analysis

Tonix Pharma disclosed 66 risk factors in its most recent earnings report. Tonix Pharma reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Tonix Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$76.20M-138.69%183.05%-83.05%
49
Neutral
$6.90B0.02-54.05%2.46%24.91%-3.14%
45
Neutral
$6.95M-30.36%86.52%
38
Underperform
$31.18M-596.70%9.74%
36
Underperform
$27.75M-132.62%-97.70%-126.39%
32
Underperform
$72.80M-23.98%-19.93%
31
Underperform
$5.02M-2639.52%19.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TNXP
Tonix Pharma
13.41
-1,049.95
-98.74%
KZIA
Kazia Therapeutics
0.98
-1.25
-56.05%
EPIX
ESSA Pharma
1.66
-7.24
-81.35%
CYCN
Cyclerion Therapeutics
2.55
-0.81
-24.11%
XCUR
Exicure
10.57
7.51
245.42%
ANVS
Annovis Bio
1.70
-7.22
-80.94%

Tonix Pharma Corporate Events

Product-Related AnnouncementsExecutive/Board Changes
Tonix Pharma Announces Key Appointment and Study Timelines
Neutral
Jan 8, 2025

Tonix Pharmaceuticals has appointed Gary Ainsworth as Vice President of Market Access, signaling potential strategic shifts in market positioning. The company also announced the expected timelines for topline data from its TNX-1300 Phase 2 study for cocaine intoxication and TNX-1500 Phase 1 study for kidney transplant rejection, marking significant steps in their product development pipeline.

Product-Related Announcements
Tonix Pharma Awaits FDA Decision on TNX-102 SL
Neutral
Dec 23, 2024

Tonix Pharmaceuticals announced that the FDA has set a Prescription Drug User Fee Act goal date of August 15, 2025, for its decision on the marketing approval of TNX-102 SL, a product candidate aimed at managing fibromyalgia. This milestone could significantly impact Tonix’s market positioning and influence stakeholder expectations within the pharmaceutical industry.

Product-Related AnnouncementsRegulatory Filings and Compliance
Tonix Pharma’s TNX-102 SL Nears FDA Approval Milestone
Positive
Dec 17, 2024

Tonix Pharmaceuticals announced the FDA’s acceptance of its New Drug Application for TNX-102 SL, a non-opioid analgesic for fibromyalgia. This acceptance marks potential progress toward introducing the first new fibromyalgia drug in over 15 years, potentially reducing reliance on opioids, and signifies a significant milestone as Tonix prepares for potential market approval in 2025.

Product-Related AnnouncementsExecutive/Board ChangesBusiness Operations and Strategy
Tonix Pharma Expands Leadership Amid Drug Development
Neutral
Dec 3, 2024

Tonix Pharmaceuticals is strategically strengthening its leadership team by appointing new executives as it prepares for significant progress with its TNX-102 SL product aimed at managing fibromyalgia. The company anticipates beginning a new study for acute stress reactions in early 2025 and awaits a potential FDA decision on its New Drug Application by August 2025. Investors are advised to consider forward-looking statements with caution due to inherent uncertainties.

Product-Related AnnouncementsBusiness Operations and Strategy
Tonix Pharma Reveals Promising TNX-801 Vaccine Data
Positive
Nov 13, 2024

Tonix Pharmaceuticals has unveiled promising data for its TNX-801 vaccine, showing it is less virulent in immune-compromised mice compared to 20th-century vaccinia vaccines. This breakthrough suggests TNX-801 could be an effective candidate in controlling mpox spread. Investors should note the company’s forward-looking statements about product development and potential growth, while being mindful of inherent market risks.

Product-Related Announcements
Tonix Pharma Unveils Promising TNX-1700 Cancer Data
Positive
Nov 8, 2024

Tonix Pharmaceuticals Holding Corp. has unveiled new data from a manuscript showing promising results of its TNX-1700 candidate in cancer treatment. Collaborating with Columbia University scientists, the study demonstrated that TNX-1700 enhanced the effects of anti-PD-1 therapy, leading to tumor regression and prolonged survival in animal models. These findings highlight TNX-1700’s potential to revolutionize immunotherapy by targeting specific immune suppressor cells, offering hope for improved cancer treatments.

Product-Related AnnouncementsBusiness Operations and Strategy
Tonix Pharma Partners for Vaccine Clinical Trial
Positive
Nov 4, 2024

Tonix Pharmaceuticals has partnered with the Kenya Medical Research Institute to launch a Phase I clinical trial for its TNX-801 vaccine aimed at preventing mpox and smallpox. This collaboration will see Tonix sponsoring the trial while KEMRI leads its execution, marking a significant step in vaccine development and regulatory approval processes. Investors should note that this announcement includes forward-looking statements about the company’s future operations and market potential.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.